<DOC>
	<DOCNO>NCT02805660</DOCNO>
	<brief_summary>Mocetinostat ( MGCD0103 ) orally administer HDAC inhibitor . Durvalumab ( MEDI4736 ) human monoclonal antibody inhibitor Programmed Cell Death Ligand ( PD-L1 ) . Durvalumab also know checkpoint inhibitor . This study evaluate combination regimen mocetinostat durvalumab subject Advanced Metastatic Solid Tumors Non-Small Cell Lung Cancer . Patients eligible study may previously receive treatment checkpoint inhibitor .</brief_summary>
	<brief_title>Phase 1/2 Study Mocetinostat Durvalumab Patients With Advanced Solid Tumors NSCLC</brief_title>
	<detailed_description>The treatment regimen begin 7-Day Lead-in Period mocetinostat alone follow start combination regimen mocetinostat durvalumab . The Recommended Phase 2 Dose mocetinostat establish Phase 1 dose escalation segment , follow evaluation clinical activity combination regimen Phase 2 .</detailed_description>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<mesh_term>Mocetinostat</mesh_term>
	<criteria>Phase 1Diagnosis advance metastatic solid tumor ; Phase 2Diagnosis NSCLC Not amenable treatment curative intent Adequate bone marrow organ function Impaired heart function Uncontrolled tumor brain Other active cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>MGCD0103</keyword>
	<keyword>MEDI4736</keyword>
	<keyword>Mocetinostat</keyword>
	<keyword>Durvalumab</keyword>
	<keyword>HDAC Inhibitor</keyword>
	<keyword>PD-L1 Inhibitor</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Phase 2</keyword>
	<keyword>Metastatic Solid Tumor</keyword>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>checkpoint inhibitor</keyword>
</DOC>